EXEGENICS INC

FORM SC 13D
(Statement of Beneficial Ownership)

Filed 6/18/1998

Address	1250 PITTSFORD-VICTOR ROAD BUILDING 200, SUITE 280
	PITTSFORD, New York 14534
Telephone	585-218-4368
CIK	0000944809
Industry	Biotechnology & Drugs
Sector	Healthcare
Fiscal Year	12/31

Generated by **EDGAR Online Pro**
http://pro.edgar-online.com

EDGAR Online

Contact **EDGAR Online**
Customer Service: 203-852-5666
Corporate Sales: 212-457-8200

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934
(Amendment No.)*

_____**Cytoclonal Pharmaceutics**_____
(Name of Issuer)

_____**Common Stock**_____
(Title of Class of Securities)

_____**23282G105**_____
(CUSIP Number)

_____4/98_____
(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G
to report the acquisition which is the
subject of this Schedule 13D, and is filing this schedule because of
Rule 13d-1(b)(3) or (4), check the
following box_____.

Check the following box if a fee is being paid with the statement _____.
(A fee is not required only if the
reporting person: (1) has a previous
statement on file reporting beneficial ownership of more than five
percent of the class of securities

described in Item1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent of less of such class.)

(Sec Rule 13d-7.)

Note: Six copies of this statement, including all exhibits, should be filed with the Commission. See Rule 13d-1(a) for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent

amendment containing information which
would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1. Name of Reporting Person

_____Bruce Meyers_____ S.S. or I.R.S. Identification No. of Above Person

_____066-40-7599_____

2. Check the Appropriate Box if a Member of a Group
(See Instructions before filling out)

a._____ b_____

3. SEC USE ONLY

---

4. Source of Funds (See instructions before filling out).

_____Personal Funds_____

5. Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e).

---

6. Citizenship or Place of Organization

_____USA_____

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
(Questions 7 - 10)

7. Sole Voting Power

_____873,625 shares_____

8. Shared Voting Power

---

9. Sole Dispositive Power

_____873,625 Shares _____

10. Shared Dispositive Power

---

11. Aggregate Amount Beneficially Owned by Each Reporting Person

_____ 873,625 shares_____

12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares
(See instructions before filling out)

---

13. Percent of Class Represented by Amount in Row (11)

_____9.844%_____

14. Type of Reporting Person (See instructions before filling out)

End of Filing

Powered By EDGAR Online

© 2005 | EDGAR Online, Inc.